GlyNAC and Insulin Resistance: A Promising Signal, Not a Diabetes Cure

The GlyNAC human trial reported a substantial improvement in HOMA-IR, a commonly used estimate of insulin resistance. The result is interesting for metabolic health, but HOMA-IR is a surrogate measure—not proof that GlyNAC prevents diabetes or cardiovascular disease.

𝗞𝗘𝗬 𝗕𝗘𝗡𝗘𝗙𝗜𝗧𝗦

• Explains HOMA-IR • Reviews the GlyNAC metabolic finding • Separates a biomarker from a clinical diagnosis • Shows why larger trials are needed

𝗪𝗛𝗔𝗧 𝗜𝗦 𝗛𝗢𝗠𝗔-𝗜𝗥

HOMA-IR uses fasting glucose and insulin measurements to estimate insulin resistance.

It is useful in research, but it is not equivalent to diagnosing diabetes.

𝗧𝗛𝗘 𝗚𝗟𝗬𝗡𝗔𝗖 𝗙𝗜𝗡𝗗𝗜𝗡𝗚

The randomized GlyNAC trial reported improvement in insulin resistance among older adults receiving GlyNAC for 16 weeks.

This is one reason researchers are interested in whether glutathione and redox biology interact with metabolic health.

𝗗𝗢𝗡'𝗧 𝗧𝗨𝗥𝗡 𝗔 𝗦𝗨𝗥𝗥𝗢𝗚𝗔𝗧𝗘 𝗜𝗡𝗧𝗢 𝗔 𝗗𝗜𝗔𝗚𝗡𝗢𝗦𝗜𝗦

Improved HOMA-IR does not demonstrate that a person no longer has insulin resistance, nor does it prove that GlyNAC prevents diabetes.

Clinical outcomes require appropriately designed trials and longer follow-up.

𝗠𝗘𝗡𝟯𝟱 𝗧𝗔𝗞𝗘𝗔𝗪𝗔𝗬

The metabolic signal is worth watching.

It should not replace proven approaches such as maintaining a healthy body weight, regular physical activity and appropriate medical screening.

𝗧𝗛𝗘 𝗕𝗢𝗧𝗧𝗢𝗠 𝗟𝗜𝗡𝗘

GlyNAC may influence metabolic biology, but it is not established as a diabetes treatment.